•
Jun 30, 2023
Edgewise Therapeutics Q2 2023 Earnings Report
Reported financial results for the second quarter of 2023 and recent business highlights.
Key Takeaways
Edgewise Therapeutics reported cash, cash equivalents and marketable securities of $310 million as of June 30, 2023. Net loss for the second quarter of 2023 was $21.5 million, or $0.34 per share.
Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy.
Advancing Phase 2 trial of EDG-5506 in Becker muscular dystrophy, which now includes a pivotal cohort called GRAND CANYON.
Advancing Phase 2 trial of EDG-5506 in Duchenne muscular dystrophy (Duchenne, LYNX).
Advancing EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy; Phase 1 start expected in 2H2023.